US Stock Market Closed

Dashboard

Retrophin, Inc. (RTRX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth
Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

CEO

Eric Dube

Employees

221

Industry

-

Sector

-

Headquarters

San Diego

Exchange

NASDAQ

Summary Stats

Market Cap

1.24B

Revenue

-

Net Income

-

EPS

-$1.71

Price-to-Earnings

-14.18

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 7 analysts

High

$38.00

Average

$32.43

Low

$27.00

Ratings calculated by 7 analysts

Buy

7

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

XX

xxx

Last Earnings Not Available

Last Earnings

Not Available

Actual

- -

Consensus

-

Report Date

-

Year Ago

-

Year Ago Change %

-

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites